Past, Present, and Future of Parkinson's Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy

Overview

Journal Mov Disord

Date 2017 Sep 10

PMID 28887905

Citations 315

Authors

J A Obeso

M Stamelou

C G Goetz

W Poewe

A E Lang

D Weintraub

D Burn

G M Halliday

E Bezard

S Przedborski

S Lehericy

D J Brooks

J C Rothwell

M Hallett

M R DeLong

C Marras

C M Tanner

G W Ross

J W Langston

C Klein

V Bonifati

J Jankovic

A M Lozano

G Deuschl

H Bergman

E Tolosa

M Rodriguez-Violante

S Fahn

R B Postuma

D Berg

K Marek

D G Standaert

D J Surmeier

C W Olanow

J H Kordower

P Calabresi

A H V Schapira

A J Stoessl

Affiliations

Soon will be listed here.

Abstract

This article reviews and summarizes 200 years of Parkinson's disease. It comprises a relevant history of Dr. James Parkinson's himself and what he described accurately and what he missed from today's perspective. Parkinson's disease today is understood as a multietiological condition with uncertain etiopathogenesis. Many advances have occurred regarding pathophysiology and symptomatic treatments, but critically important issues are still pending resolution. Among the latter, the need to modify disease progression is undoubtedly a priority. In sum, this multiple-author article, prepared to commemorate the bicentenary of the shaking palsy, provides a historical state-of-the-art account of what has been achieved, the current situation, and how to progress toward resolving Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society.

Citing Articles

Male sex accelerates cognitive decline in GBA1 Parkinson's disease.

Caminiti S, Avenali M, Galli A, Malito R, Cuconato G, Galandra C NPJ Parkinsons Dis. 2025; 11(1):41.

PMID: 40038314 PMC: 11880540. DOI: 10.1038/s41531-025-00883-7.

Ferroptosis role in complexity of cell death: unrevealing mechanisms in Parkinson's disease and therapeutic approaches.

Awasthi A, Maparu K, Singh S Inflammopharmacology. 2025; .

PMID: 39998712 DOI: 10.1007/s10787-025-01672-7.

Viscous damping of tremor using a wearable robot with an optimized mechanical metamaterial.

Raghavendra Kulkarni S, Accoto D, Campolo D Wearable Technol. 2025; 5():e20.

PMID: 39811474 PMC: 11729489. DOI: 10.1017/wtc.2024.15.

Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.

Xing C, Chen H, Bi W, Lei T, Hang Z, Du H Int J Mol Sci. 2025; 25(24.

PMID: 39769209 PMC: 11679250. DOI: 10.3390/ijms252413446.

Sub-second characterization of locomotor activities of mouse models of Parkinsonism.

Berezhnoi D, Chehade H, Simms G, Chen L, Chu H bioRxiv. 2025; .

PMID: 39763733 PMC: 11703164. DOI: 10.1101/2024.12.26.630411.

References

Richard I, McDermott M, Kurlan R, Lyness J, Como P, Pearson N . A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012; 78(16):1229-36. PMC: 3324323. DOI: 10.1212/WNL.0b013e3182516244. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Postuma R, Lang A, Gagnon J, Pelletier A, Montplaisir J . How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012; 135(Pt 6):1860-70. DOI: 10.1093/brain/aws093. View

Cantuti-Castelvetri I, Lin M, Zheng K, Keller-McGandy C, Betensky R, Johns D . Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging. 2005; 26(10):1343-55. DOI: 10.1016/j.neurobiolaging.2004.11.008. View

Brice A . Genetics of Parkinson's disease: LRRK2 on the rise. Brain. 2005; 128(Pt 12):2760-2. DOI: 10.1093/brain/awh676. View

Vilarino-Guell C, Wider C, Ross O, Dachsel J, Kachergus J, Lincoln S . VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011; 89(1):162-7. PMC: 3135796. DOI: 10.1016/j.ajhg.2011.06.001. View

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee C . Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain. 2009; 132(Pt 11):2970-9. DOI: 10.1093/brain/awp209. View

Cooper I . Ligation of the anterior choroidal artery for involuntary movements; parkinsonism. Psychiatr Q. 1953; 27(2):317-9. DOI: 10.1007/BF01562492. View

10.

LeWitt P, Fahn S . Levodopa therapy for Parkinson disease: A look backward and forward. Neurology. 2016; 86(14 Suppl 1):S3-12. DOI: 10.1212/WNL.0000000000002509. View

11.

Hilker R, Thomas A, Klein J, Weisenbach S, Kalbe E, Burghaus L . Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005; 65(11):1716-22. DOI: 10.1212/01.wnl.0000191154.78131.f6. View

12.

Kordower J, Brundin P . Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another?. Neuropsychopharmacology. 2008; 34(1):254. DOI: 10.1038/npp.2008.161. View

13.

Dickson D . Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012; 2(8). PMC: 3405828. DOI: 10.1101/cshperspect.a009258. View

14.

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

15.

SVENNILSON E, TORVIK A, Lowe R, LEKSELL L . Treatment of parkinsonism by stereotatic thermolesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatr Scand. 1960; 35(3):358-77. DOI: 10.1111/j.1600-0447.1960.tb07606.x. View

16.

Visanji N, Brotchie J, Kalia L, Koprich J, Tandon A, Watts J . α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends Neurosci. 2016; 39(11):750-762. DOI: 10.1016/j.tins.2016.09.003. View

17.

Hoogland J, Boel J, de Bie R, Geskus R, Schmand B, Dalrymple-Alford J . Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Mov Disord. 2017; 32(7):1056-1065. DOI: 10.1002/mds.27002. View

18.

Bergstrom A, Kallunki P, Fog K . Development of Passive Immunotherapies for Synucleinopathies. Mov Disord. 2015; 31(2):203-13. DOI: 10.1002/mds.26481. View

19.

Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31):13010-5. PMC: 2722313. DOI: 10.1073/pnas.0903691106. View

20.

Lang A . A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord. 2011; 26(5):775-83. DOI: 10.1002/mds.23609. View